medigraphic.com
ISSN 1561-3127 (Electronic)
ISSN 0864-3466 (Print)

2014, Number 4

<< Back Next >>

Revista Cubana de Salud Pública 2014; 40 (4)

The discreet charm of drugs

Pérez PJL, Jiménez RD

Language: Spanish
References: 19
Page: 349-360
PDF size: 134.04 Kb.


ABSTRACT

This article summarized a group of lectures on the world drug industry delivered from 2010 to 2013 in a number of national and international fora. Taking into account that a pharmaceutical is a social asset used to prevent diseases and recover human health, the behavior of the drug production and consumption worldwide shows a awkward overview in terms of the real needs of the population. An analysis was made on the elements involved in such behavior, beginning with a characterization of the world current drug industry and analyzing three aspects related to the results: medical-drug research, medical promotion and information and operation of the national drug regulatory agencies. The world drug industry has provided huge benefits for the treatment of diseases and this is an undeniable fact; however, the Big Pharma needs to be profitable. Globalization and neoliberalism have created patterns of incentives and behaviors mainly based on the market interests. We should be aware of that in the future. This new century poses new challenges for the peoples, their governments and for the Big Pharma in terms of health, disease and how to face it.


REFERENCES

  1. Bjelakovic, G. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention. JAMA. 2007;297(8):842-57. doi: 10.1001/jama 297.8.842 Revista Cubana de Salud Pública. 2014;40(4):349-360 http://scielo.sld.cu 359

  2. An innovative challenge to the pharmaceutical industry [editorial]. Lancet. 2002;360(9343):1341.

  3. National Institute for Health Care Management. Changing patterns of pharmaceutical innovation. Washington, D.C.: NIHCM Foundation; 2002 [cited 2009 Oct 23]. Available from: http://www.nihcm.org/~nihcmor/pdf/innovations.pdf

  4. Koch K. Schering uses German Medical Association to promote HRT. BMJ. 2003;326 (7400):1161.

  5. Collier J, Iheanacho I. The pharmaceutical industry as an informant. Lancet. 2002;360(9343):1405-9.

  6. Velez LA. Actualización del conocimiento médico, ¿una utopía? [editorial]. CES Med. 1991;5(1):7-8. ld: 515476.

  7. Laporte JR. Los laboratorios gastan casi el triple en promoción que en investigación. La vanguardia. 17 May 2011 [citado 22 Ene 2014];Sanidad. Disponible en: http://www.lavanguardia.com/salud/20110517/54155590168/laporte-loslaboratorios- gastan-casi-el-triple-en-promocion-que-en-investigacion.html

  8. Ugalde A, Homedes N. Medicamentos para lucrar. La transformación de la industria farmacéutica. Salud colectiva. 2009;5(3):10-4.

  9. Outterson K. Pharmaceutical arbitrage: balancing access and innovation in international prescription drug markets. Yale J Health Policy, Law Ethics. 2005;5(1):193-291.

  10. Batt S. Marching to different drummers: Health Advocacy Groups in Canada and Funding from the Pharmaceutical Industry. Canadá: Women and Health Protection; 2005 [cited 2009 Oct 23]. Available from: http://www.whpapsf. ca/pdf/corpFunding.pdf

  11. Multan con 2 200 millones de dólares… La Jornada. 5 Nov 2013 [citado 22 Ene 2014]; Economia. Disponible en: http://www.jornada.unam.mx/2013/11/05/economia/022n4eco

  12. La Farmacéutica Glaxo pagará más de 3 000 millones de dólares. El Mundo. 17 May 2011 [citado 22 Ene 2014];Salud. Disponible en: http://www.elmundo.es/elmundosalud/2011/11/03/noticias/1320351605.html

  13. Balaguer F. Enfermedad no rentable. La vanguardia. 17 May 2011 [citado 13 Ago 2007];Salud. Disponible en: http://www.lavanguardia.com/20070813/54061300258/enfermedad-no-rentablefrancesc- balaguer-i-sancho.html

  14. Mintzes B. For and against Direct to consumer advertising is medicalising normal human experience. BMJ. 2002;324(7342):808-9.

  15. Woleshin S, Schwartz LM. Giving legs to Restless legs Syndrome. A case study of how the media helps make people sick. Plos Med. 2006(4):e70. Revista Cubana de Salud Pública. 2014;40(4):349-360 http://scielo.sld.cu 360

  16. Médica Sur. México, D. F.: Médica Sur; c2014 [citado 23 Ene 2014]. Síndrome de piernas inquietas. Disponible en: http://www.medicasur.com/es_mx/ms/ms_tmsl_psi_Sindrome_de_Piernas_Inquiet as

  17. Intermittent Explosive Disorder. Arch Gen Psyquiatric. 2006;63(6):669-78.

  18. ICH Official web site. Suiza: ICH; c2014 [actualizado 2014; citado 23 Ene 2014]. Disponible en: http://www.ich.org

  19. 19.Figueras A, Laporte JR. Failure of the therapeutic chain as a cause of drug ineffectiveness. BMJ. 2003;326(7395):895-6.




2020     |     www.medigraphic.com